City of Hope | Strategic Alliance Partnership

In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.

Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.

Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.

City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic castration-resistant prostate cancer (mCRPC).

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

Institute for Value-Based Medicine event with City of Hope.

Andrew Leitner, MD, of City of Hope, discusses the challenges of integrating supportive care into cancer treatment and proposes solutions to improve access for patients from underserved communities.

Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, emphasizes the need for a sustainable health care system that balances cost with care so patients can achieve the best survival and quality of life after a cancer diagnosis.

Andrew Leitner, MD, City of Hope, highlights the essential role of supportive care in improving the quality of life of patients with cancer undergoing treatment.

Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, highlights challenges in cancer care, focusing on improving access to accurate diagnoses and treatments, promoting patient-centered approaches, and fostering collaboration to achieve better outcomes.

Joseph Alvarnas, MD, of City of Hope, discusses how he envisions the future of cancer care over the next decade.

Joseph Alvarnas, MD, of City of Hope, recaps yesterday's Institute for Value-Based Medicine® (IVBM) event on value-based oncology care, emphasizing patient-centered approaches and how attendees can apply these insights in their daily practice.

Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.

We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.

In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.

In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.

Within the GAIN-S model, geriatric care assessments among older patients with cancer are combined with care interventions, and it is delivered soon before patients have an intervention on their cancer therapy, says William Dale, MD, PhD, FASCO, City of Hope.

Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.

Clinical use of liquid biopsies to determine the likelihood of CRC is the goal based on its effectiveness in recent studies.

MicroRNAs could be a key to future testing for colorectal cancer (CRC) and determining treatment.

Ajay Goel, PhD, AGAF, discusses study findings that could help in earlier detection of lymph node metastases and colorectal cancer (CRC).

Ajay Goel, PhD, AGAF, explains the significance of 2 new studies that found that early-onset colorectal cancer (EOCRC) and recurrence in CRC could both be predicted using new blood and tissue tests.

The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care.

Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

Findings from PREVENT-HF put to rest the idea that once remodeling in the heart's structure starts following anthracyclines that nothing can be done to treat it.